Research Triangle Park, NC – July 31, 2015 – Quintiles Transnational Holdings Inc. (“Quintiles”) (NYSE: Q) announced today the pricing of an underwritten, secondary public offering of 7,000,000 shares of its common stock by certain of its existing shareholders, including investment funds associated with Bain Capital Investors, LLC, affiliates of TPG Global, LLC, affiliates of 3i Corporation and Temasek Life Sciences Private Limited (the “Selling Shareholders”) at a price to the public of $77.85 per share. Quintiles will not receive any proceeds from the sale of the shares by the Selling Shareholders in this offering.
Morgan Stanley is acting as the sole underwriter for this offering.
The offering is expected to close on August 5, 2015, subject to customary closing conditions.
An...

This White Paper discusses and emphasizes the importance of ensuring the highest possible data retention rates in clinical outcome trials. It presents a case study involving the TRILOGY Acute Coronary Syndromes clinical trial. In collaboration with the Sponsor project team, Quintiles and Duke Clinical Research Institute developed and implemented a robust data retention process that led to a subject lost-to-follow-up rate of only 0.2% at study...

Research Triangle Park, NC – July 30, 2015 – Quintiles Transnational Holdings Inc. (“Quintiles”) (NYSE: Q) announced today the launch of an underwritten, secondary public offering of 7,000,000 shares of its common stock by certain of its existing shareholders, including investment funds associated with Bain Capital Investors, LLC, affiliates of TPG Global, LLC, affiliates of 3i Corporation and Temasek Life Sciences Private Limited (the “Selling Shareholders”). Quintiles is not offering any stock in this transaction and will not receive any proceeds from the sale of the shares by the Selling Shareholders in the offering.
Morgan Stanley is acting as the sole underwriter for this offering.
An automatic shelf registration statement (including a prospectus) relating to the offering of...

Research Triangle Park, NC – July 29, 2015 – Quintiles Transnational Holdings Inc. (“Quintiles” or the “Company”) (NYSE: Q) today reported its financial results for the quarter ended June 30, 2015.
9.8% constant currency service revenue growth compared to the second quarter of 2014
20.0% increase in diluted adjusted EPS to $0.78 per share compared to the second quarter of 2014, second quarter GAAP reported diluted EPS of $0.67
7.6% net new business growth compared to the second quarter of 2014 representing a 1.23 book-to-bill ratio
$2.75 billion debt refinancing and a $250 million share repurchase
Increasing full year 2015 service revenue constant currency growth guidance to 8.5% - 9.5% compared to full year 2014 and increasing diluted adjusted EPS guidance to...

Jane Eisner, Senior Vice President, Customer Solutions Management Group, discusses the critical decisions facing Biopharma customers in developing their clinical pipelines and the benefits of working in collaboration to find the best end-to-end...

Explore the current approaches to conducting real-world post-authorization studies and surveillance activity for vaccines, including those conducted under the interim EMA guidance for enhanced safety surveillance for seasonal influenza vaccines.
Assessment of the safety and effectiveness of seasonal and pandemic influenza vaccines as well as other newly introduced vaccines presents different considerations and challenges than for other medical products. Widespread use in healthy populations, including children, pregnant women, and the elderly establishes high societal requirements for demonstrated benefit (effectiveness) and product...

Laura Marquis, Vice President & Global Head of Emerging Biopharma at Quintiles, discusses the strategic importance and growing role emerging biopharmas are playing in the global biopharmaceutical market, and how Quintiles is adapting to meet their unique...

A Clinical Evaluation Report (CER) is a living document required for the EU market for all classes of new and existing devices, detailing the clinical evaluation of a product throughout its life-cycle. Whilst the requirement to have a CER is not new, it is subject to more intense scrutiny by Notified Bodies in the conformity assessment phase, and CERs are increasingly being assessed in the post-market...

With rapid advances in genomic technologies, today their value extends beyond the discovery phase of drug research. Here, Dr. Patrick Hurban explains how to select the right genomic technology to gain the right insights that successfully advance research and development...

Business domain expertise is critical to the success of IT projects. Leverage Quintiles’ deep IT and clinical domain expertise to develop, build and operate IT systems and services tailored to meet your...

RESEARCH TRIANGLE PARK, N.C. and MADISON, N.J. – July 2, 2015 – Quintiles and Quest Diagnostics today announced the launch of Q2 Solutions, their new combined clinical trials laboratory services organization. Q2 Solutions brings together the clinical trials laboratory operations of the two parent organizations to provide biopharmaceutical customers with the diverse capabilities and end-to-end services required in the rapidly evolving biopharmaceutical industry. Today’s launch of Q2 Solutions is the result of the close of the previously announced global clinical trials laboratory services joint-venture transaction.
Q2 Solutions is strongly positioned as the second-largest central laboratory services company in the world and provides services to customers across all segments of the...

RESEARCH TRIANGLE PARK, N.C. – July 1, 2015 – Quintiles Transnational Holdings Inc. (NYSE: Q) will release its second-quarter 2015 financial results Wednesday, July 29, 2015 prior to its quarterly earnings call at 8:00 a.m. EDT.
The conference call will be accessible, live via webcast, on the Investor Relations section of the Quintiles website at www.quintiles.com/investors. To participate via telephone, please dial +1 (855) 710-5091 in the United States or +1 (706) 902-0591 outside the United States, approximately 15 minutes before the scheduled start of the call.
An archived edition of the conference call will be available online at www.quintiles.com/investors after 1:00 p.m. EDT on Wednesday, July 29th.
About Quintiles
Quintiles (NYSE: Q) helps biopharma and other healthcare...

This insight brief explores the benefits of Model-based Drug Development (MBDD) for emerging biopharma companies. MBDD is the process of leveraging modeling and simulation throughout the project life cycle to predict trial results and inform planning and design decisions.
MBDD is a proven and often effective method for reducing the costly delays and changes that plague typical development efforts by enabling project teams to select the right dose, estimate patient recruitment, and optimize protocol, study and program...

Historically, lifecycle management (LCM) has been focused primarily on market expansion and product life extension. However in today’s rapidly changing healthcare environment, this is no longer enough. You must also focus on product protection and differentiation as strategies for delivering real value to all stakeholders in the healthcare system.
At Quintiles, we believe in order for your product to succeed in the changing health landscape, you must implement an integrated lifecycle management strategy that meets payer...

Understanding the needs of local payers is more important than ever for biopharma. It can be challenging to uncover the key requirements of a local market, and even more difficult to prove how a drug can help fulfill the unmet needs of the local population.
With payers becoming more sophisticated in their evidentiary needs, Clinical Commissioning Groups (CCGs) now require data that is tailored to their local healthcare economy. The data generated needs to go beyond regulatory approval; it needs to prove cost effectiveness, provide checkpoints between payer and biopharma, and ensure the removal of any uncertainties that may result in barriers to market access.
Quintiles has a network of strong local market access teams to help support you in reaching local decision makers and...

Non-adherence to medicine is a major concern for the UK health economy. The National Institute for Health and Care Excellence (NICE) estimates that £4 billion of medicine is currently not used correctly, and as a result, biopharma must strive to understand the varying types and causes of non-adherence.
The local care pathway should be under focus if biopharma is to tackle nonadherence. By using real patient and treatment data to analyze core pathway frailties that contribute to non-adherence. solutions can be developed to help improve that core pathway, and more critically, explore what motivates individual patients to adhere. Where a patient is on the treatment pathway is also vital, as recently diagnosed patients have different needs to those who have lived for several years with a...

A patient registry is defined as "an organized system that uses observational study methods to collect uniform data (clinical and other) to evaluate specified outcomes for a population defined by a particular disease, condition, or exposure. A registry also serves one of more predetermined scientific, clinical, or policy purposes." Patient registries may be used for a variety of purposes, including one or more of the following: effectiveness research for drugs or devices, natural history of disease, post-marketing commitments or safety monitoring, quality improvement programs, certification programs (e.g., for physicians to retain membership in a professional medical organization), and surveillance programs (e.g., to track vaccination...

Pediatric studies require specialized expertise to ensure study design and protocol-required procedures are appropriate for children and include support for the family during the trial.
Through our Pediatric Center of Excellence, Quintiles brings together the therapeutic, regulatory and operational expertise to help you design and execute a feasible pediatric...